Articles from Babson Diagnostics

BetterWay™ blood testing by Babson Diagnostics was announced the winner in the Health and Biotech category of the prestigious 26th Annual SXSW® Innovation Awards competition. BetterWay was recognized for its new, customer-friendly blood testing technology that collects pea-sized samples from the fingertip instead of tubes of blood from the arm.

BetterWay™ blood testing by Babson Diagnostics is excited to bring its innovative blood testing technology to the 2025 SXSW® Conference and Festivals, a gathering of the world’s foremost innovators, creatives, and thought leaders across industries. SXSW attendees can experience firsthand how BetterWay has reimagined blood testing to make it friendly, convenient, and affordable without sacrificing the accuracy and efficiency of laboratory analysis.

Babson Diagnostics, a science-first healthcare technology company, today announced that BetterWay™ blood testing is a finalist for the 2025 South by Southwest (SXSW) Innovation Awards in the Health & Biotech category.

Babson Diagnostics, a science-first healthcare technology company, today announced that BD (Becton, Dickinson and Company), a leading global medical technology company, has made an investment in Babson, strengthening their long-term strategic partnership to expand access to blood testing.

Babson Diagnostics, a science-first healthcare technology company, is excited and proud to announce the launch of its groundbreaking blood testing service. BetterWay blood testing represents a significant advancement in an essential medical service, providing a patient-preferred experience and enabling high-quality testing in more convenient settings.

Babson Diagnostics, a science-first healthcare technology company, today announced that it will use ELLKAY’s leading lab-ordering solution to make it easy for clinicians to order BetterWay™ blood testing. The partnership marks a significant milestone in Babson’s commitment to support clinicians in delivering a better patient experience and improving adherence to essential testing.

Please replace the release dated May 3, 2024 with the following corrected version due to multiple revisions.

Babson Diagnostics, a science-first healthcare technology company, today announced the newest innovation in its BetterWay™ blood testing ecosystem has completed validation testing. The company created a unique hand-warming technology specifically designed to support the collection of high-quality blood samples from a fingertip.

Babson Diagnostics, a science-first health technology company, announced today that it will launch BetterWay™ blood testing with three retail partners in Austin and San Antonio. BetterWay brings blood testing into the 21st century, making it less invasive, more convenient, and accessible for consumers.

Babson Diagnostics, a science-first health care technology company, today announced its new, highly automated microsample laboratory has been awarded accreditation by the College of American Pathologists (CAP) based on the results of a recent on-site inspection.

Babson Diagnostics™, a science-first, health care technology company, today announced that a key piece of its BetterWay™ Blood Testing ecosystem has achieved 510(k) clearance from the U.S. Food and Drug Administration. These regulatory clearances pave the way for Babson to bring BetterWay—a first-of-its-kind blood testing service—to market next year.

Babson Diagnostics, a science-first health care technology company, today announced the addition of a clinical advisor who will bring valuable insights of the medical community in the ongoing development and introduction of the company’s new diagnostic blood testing service, BetterWay™. Andrew Carroll, M.D., a family physician and clinical assistant professor at the University of Arizona College of Medicine, will provide advice and counsel about clinical best practices and review validation data and reports.

Babson Diagnostics, a science-first healthcare technology company, and ClosedLoop, the leading healthcare data science platform, today announced their team was selected as the first-place winner of the ‘Help with Hemolysis’ Data Analytics Challenge. As winners, the Babson and ClosedLoop team will present their approach for using data science to solve the real-world laboratory challenge of hemolysis during a scientific session titled “Blood & Bytes: Reducing sample quality errors in clinical laboratories using data science” at the 2023 AACC Annual Scientific Meeting & Clinical Lab Expo in Anaheim on July 23-27, 2023.

Babson Diagnostics, a science-first, health care technology company, today announced BetterWay™ Blood Testing, the name of its new diagnostic blood testing service that is designed around the most important element of testing – the customer.

Babson Diagnostics, a science-first health care technology company, today announced that it continues to grow its management team with the addition of four key leaders. The new team members bring skill sets and experience that will support the commercial launch of its blood testing ecosystem, which reimagines blood testing from collection to sample preparation to analysis, to better meet the needs of the modern clinician and consumer.

Babson Diagnostics, a science-first, health care technology company, today announced a media partnership with the Pharmacy Podcast Network in connection with the 2022 National Association of Chain Drug Stores’ Total Store Expo, the largest gathering of retailers and suppliers in the health and wellness industry.

Babson Diagnostics, a science-first healthcare technology company, today announced its laboratory has been awarded accreditation by the College of American Pathologists (CAP) based on the results of a recent site inspection.

Babson Diagnostics, a science-first healthcare technology company, today announced that it has expanded its leadership team with key senior hires who will advance the development and commercialization of its unique blood-testing system that unites innovations in collection, sample handling, and analysis.

Babson Diagnostics, a science-first medical technology company, today announced the appointments of Kristie Stanton as vice president of marketing and Vicente Armendariz as vice president of strategy, effective immediately. Stanton and Armendariz will report to Chief Executive Officer David Stein, Ph.D., and will help drive the commercialization and growth of Babson’s novel technologies that will transform the entire diagnostic blood testing process.

Babson Diagnostics, a transformative medical technology company improving customer access to diagnostic blood testing, today announced the closing of $31 million in an oversubscribed Series B funding round, led by Emerald Development Managers, with full participation by existing investors Siemens Healthineers, Prism Ventures, and Lago Consulting Group.